DERMJourney Medical Corporation Common Stock
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 Journey Medical (DERM) Q2 2026 Earnings Call Transcript Emrosi prescriptions hit 14,000 in July as payer coverage expands and margins improve. | ||
Journey Medical Corp (DERM) (Q2 2026) Earnings Call Highlights: Emrosi Surges 20% Sequentially, ... Journey Medical Corp (DERM) narrows net loss to $300K as Emrosi prescriptions hit all-time highs and payer access expands. | ||
 Journey Medical Corporation Q2 2026 Earnings Call Summary Moby summary of Journey Medical Corporation's Q2 2026 earnings call | ||
 Fortress Biotech Q2 Earnings Call Highlights Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Executive Officer Claude Maraoui said the company generated positive EBITDA in the second quarter and | ||
 Journey Medical Q2 Earnings Call Highlights Journey Medical (NASDAQ:DERM) reported higher second-quarter revenue and a sharply narrower net loss as sales of its rosacea treatment EMROSI continued to grow, supported by rising prescription volume, broader prescriber adoption and improving payer reimbursement. Total revenue for the second quart | ||
 Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. | ||
 Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates Journey Medical (DERM) delivered earnings and revenue surprises of 0.00% and -1.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50.00% and -11.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates Ardelyx (ARDX) delivered earnings and revenue surprises of -40.00% and -2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||